Peer-Reviewed Publications

      A network-based approach to quantifying the impact of biologically active substances

      Hoeng, J.; Deehan, R.; Pratt, D.; Martin, F.; Sewer, A.; Thomson, T. M.; Drubin, D. A.; Waters, C. A.; de Graaf, D.; Peitsch, M. C.
      Published
      Dec 1, 2011
      DOI
      10.1016/j.drudis.2011.11.008
      PMID
      22155224
      Link to publication
      Topic
      Summary

      Society increasingly demands close scrutiny of the potential health risks of long-term exposure to biologically active substances, such as therapeutic drugs or environmental toxins. Such risks are typically assessed a posteriori through clinical epidemiology studies. However, disease might take decades to manifest, at a point where changes in therapeutic regime, life style or exposure would not prevent disease onset.

      Related Publications

      Evaluating Use Patterns of a Closed Electronic Nicotine Delivery System Among Adults in the United States Who Smoke Cigarettes Daily: 8-Week Actual Use Study

      Perception and Behavior

      Barriers to stop smoking (BASS): Results and insights from four years of empirical research in Germany

      Perception and Behavior

      Unlocking a decade of tobacco heating system post-market surveillance

      Post-Market Studies and Surveillance Study

      Reasons for oral nicotine product use among adults who smoke or use smoke-free products in Germany - Results from the Barrier to Stopping smoking (BASS) survey

      Perception and Behavior

      Misunderstanding nicotine delivery: Discussion on nicotine pouches

      Nicotine

      AeroSolved: Wall Boundary Conditions for Liquid Multispecies Aerosol Deposition at Transient and High-Humidity Flows

      Aerosol Physics

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.